Table 4.
Id-1 expression and clinicopathologic characteristics
| Id1 weak | Id1 strong | p-value | ||
|---|---|---|---|---|
|
|
||||
| N = 50 | N = 25 | |||
| Age | Mean ± S.D. | 61.9 ± 9.6 | 62.6 ± 8.1 | 0.743 |
| Sex | male | 38 (76.0%) | 18 (72.0%) | 0.707 |
| female | 12 (24.0%) | 7 (28.0%) | ||
| Diagnosis | SCC | 35 (70.0%) | 11 (44.0%) | 0.031 |
| AC | 15 (30.0%) | 13 (52.0%) | ||
| ASC | 0 (0.0%) | 1 (4.0%) | ||
| T stage | 1 | 20 (40.0%) | 6 (24.0%) | 0.251 |
| 2 | 25 (50.0%) | 18 (72.0%) | ||
| 3 | 5 (10.0%) | 1 (4.0%) | ||
| T stage 2 | 1 | 20 (40.0%) | 6 (24.0%) | 0.205 |
| 2 + 3 | 30 (60.0%) | 19 (76.0%) | ||
| N stage | 0 | 48 (96.0%) | 25 (100.0%) | > 0.99 |
| 1 | 1 (2.0%) | 0 (0.0%) | ||
| 2 | 1 (2.0%) | 0 (0.0%) | ||
| N stage 2 | 0 | 48 (96.0%) | 25 (100.0%) | 0.550 |
| 1 + 2 | 2 (4.0%) | 0 (0.0%) | ||
| VEGF | weak | 45 (90.0%) | 9 (36.0%) | < 0.001 |
| strong | 5 (10.0%) | 16 (64.0%) | ||
| Metastasis | negative | 48 (96.0%) | 19 (76.0%) | 0.014 |
| positive | 2 (4.0%) | 6 (24.0%) | ||
| Recurrence | negative | 46 (92.0%) | 18 (72.0%) | 0.035 |
| positive | 4 (8.0%) | 7 (28.0%) | ||
SCC: Squamous cell carcinoma; AC: Adenocarcinoma; ASC: Adenosquamous cell carcinoma.